Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Oct 1, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.8K

Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.

Eugene Kim1, Yanwen Jiang2, Tao Xu3

  • 1Department of Biostatistics, Product Development, Genentech, Inc, 1 DNA Way, MS 444A, South San Francisco, CA, 94080, USA.

BMC Cancer
|March 3, 2022
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial.

Blood neoplasia·2026
Same author

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Circulating tumor DNA at baseline as a prognostic marker in untreated follicular lymphoma.

Haematologica·2026
Same author

Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

Blood·2026
Same author

First-line immunochemotherapy for indolent lymphoma does not affect muscle volume: a <i>post hoc</i> analysis of 472 patients in long-term remissions from the GALLIUM study.

Leukemia & lymphoma·2026
Same author

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.

American journal of hematology·2026

Non-negative matrix factorization (NMF) with targeted sequencing identifies diffuse large B-cell lymphoma (DLBCL) molecular subsets. The BCL2/EZH2 group showed a trend towards improved survival, suggesting potential benefit from venetoclax therapy.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous cancer with distinct molecular subsets.
  • Non-negative matrix factorization (NMF) has previously identified six molecular clusters in DLBCL using whole exome sequencing data.

Purpose of the Study:

  • To apply NMF-clustering to targeted sequencing data from the GOYA and CAVALLI clinical trials in de novo DLBCL.
  • To identify molecular subsets and assess their clinical relevance in DLBCL patients.

Main Methods:

  • NMF-clustering was applied to targeted sequencing data from the FoundationOne Heme® panel.
  • Analysis included biopsy samples, survival outcomes, and RNA-Seq data from 423 patients in the GOYA study and 86 patients in the CAVALLI study.
  • Patients in GOYA received obinutuzumab (G)-CHOP vs rituximab (R)-CHOP; CAVALLI patients received venetoclax+[G/R]-CHOP.
Keywords:
Diffuse large B-cell lymphomaGenomicsNext-generation sequencingObinutuzumabReal worldRituximabVenetoclax

More Related Videos

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
10:41

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Published on: March 29, 2017

11.9K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

Related Experiment Videos

Last Updated: Oct 1, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.8K
Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
10:41

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Published on: March 29, 2017

11.9K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

Main Results:

  • In the GOYA study, four previously reported NMF clusters were observed: MYD88/CD79B, BCL2/EZH2, NOTCH2/TNFAIP3, and no mutations.
  • Mutation profiles and clinical associations for MYD88/CD79B and BCL2/EZH2 groups were consistent with prior NMF studies.
  • The CAVALLI study yielded three clusters (MYD88/CD79B-, BCL2/EZH2-like, and no mutations), with a trend for improved outcomes in the BCL2/EZH2 group.

Conclusions:

  • NMF combined with targeted sequencing is effective for identifying prognostic subsets in DLBCL.
  • The improved overall survival trend in the BCL2/EZH2 group aligns with venetoclax's mechanism of action.
  • Targeted sequencing and NMF can identify DLBCL patients likely to benefit from venetoclax therapy.